CVKD
Cadrenal Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.06
−2.75%Oct 7, 2026, 11:00 UTC
Cadrenal Therapeutics, Inc. initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its asset portfolio.
Source:Sep 29, 2026, 20:14 UTC
Cadrenal Therapeutics, Inc. appointed Quang X. Pham as a Class I director effective September 24, 2026.
Sep 25, 2026, 21:19 UTC
Stark Focus Group, Inc. appointed Matthew Szot as Chief Financial Officer, effective October 8, 2026.
Aug 31, 2026, 12:00 UTC
Cadrenal Therapeutics announced positive feedback from an FDA Type D meeting held on July 28, 2026, regarding its Phase 3 registration study of CAD-1005 for heparin-induced thrombocytopenia.
Source:Jul 21, 2026, 12:00 UTC
Cadrenal Therapeutics launches a partnering process for its cardiac acute critical care assets, including CAD-1005, frunexian, and tecarfarin, following ISTH data presentation.
Source:Jul 1, 2026, 07:56 UTC
Cadrenal Therapeutics priced a private placement to raise up to $8.8 million.
Source:Jun 3, 2026, 00:00 UTC
Cadrenal Therapeutics announced that Matthew K. Szot departed as Chief Financial Officer by mutual agreement, effective May 28, 2026, and appointed Quang X. Pham as interim Chief Financial Officer and interim Principal Accounting Officer, effective the same date.